TY - JOUR
T1 - Structural and kinetic characterization of Porphyromonas gingivalis glutaminyl cyclase
AU - Lamers, Sebastiaan
AU - Feng, Qiaoli
AU - Cheng, Yili
AU - Yu, Sihong
AU - Sun, Bo
AU - Lukman, Maxwell
AU - Jiang, Jie
AU - Ruiz-Carrillo, David
N1 - Publisher Copyright:
© 2021 De Gruyter. All rights reserved.
PY - 2021/6/1
Y1 - 2021/6/1
N2 - Porphyromonas gingivalis is a bacterial species known to be involved in the pathogenesis of chronic periodontitis, that more recently has been as well associated with Alzheimer’s disease. P. gingivalis expresses a glutaminyl cyclase (PgQC) whose human ortholog is known to participate in the beta amyloid peptide metabolism. We have elucidated the crystal structure of PgQC at 1.95 Å resolution in unbound and in inhibitor-complexed forms. The structural characterization of PgQC confirmed that PgQC displays a mammalian fold rather than a bacterial fold. Our biochemical characterization indicates that PgQC uses a mammalian-like catalytic mechanism enabled by the residues Asp149, Glu182, Asp183, Asp218, Asp267 and His299. In addition, we could observe that a non-conserved Trp193 may drive differences in the binding affinity of ligands which might be useful for drug development. With a screening of a small molecule library, we have identified a benzimidazole derivative rendering PgQC inhibition in the low micromolar range that might be amenable for further medicinal chemistry development.
AB - Porphyromonas gingivalis is a bacterial species known to be involved in the pathogenesis of chronic periodontitis, that more recently has been as well associated with Alzheimer’s disease. P. gingivalis expresses a glutaminyl cyclase (PgQC) whose human ortholog is known to participate in the beta amyloid peptide metabolism. We have elucidated the crystal structure of PgQC at 1.95 Å resolution in unbound and in inhibitor-complexed forms. The structural characterization of PgQC confirmed that PgQC displays a mammalian fold rather than a bacterial fold. Our biochemical characterization indicates that PgQC uses a mammalian-like catalytic mechanism enabled by the residues Asp149, Glu182, Asp183, Asp218, Asp267 and His299. In addition, we could observe that a non-conserved Trp193 may drive differences in the binding affinity of ligands which might be useful for drug development. With a screening of a small molecule library, we have identified a benzimidazole derivative rendering PgQC inhibition in the low micromolar range that might be amenable for further medicinal chemistry development.
KW - 5,6-dimethylbenzimid-azole
KW - Alzheimer’s disease
KW - Glutaminyl cyclase
KW - Periodontitis
KW - Porphyromonas gingivalis
KW - Pyroglutamate
KW - Rossmann fold
UR - http://www.scopus.com/inward/record.url?scp=85104410986&partnerID=8YFLogxK
U2 - 10.1515/hsz-2020-0298
DO - 10.1515/hsz-2020-0298
M3 - Article
C2 - 33823093
AN - SCOPUS:85104410986
SN - 1431-6730
VL - 402
SP - 759
EP - 768
JO - Biological Chemistry
JF - Biological Chemistry
IS - 7
ER -